glibenclamide

ApprovedSmall molecule

Novo Nordisk

glibenclamide is one of 305 small molecule programs targeting Endothelial Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

304

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endothelial DysfunctionActive, not recruiting

Gestational DiabetesActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Oxidative StressActive, not recruiting

Brain EdemaActive, not recruiting

Intracerebral HemorrhageActive, not recruiting

Diabetes MellitusActive, not recruiting

HypoglycemiaActive, not recruiting

Multiple SclerosisActive, not recruiting

Type 2 DiabetesActive, not recruiting

Endothelial DysfunctionApproved

Active, not recruiting

Gestational DiabetesPhase 3

Active, not recruiting

Type 2 Diabetes MellitusApproved

Active, not recruiting

Oxidative StressPreclinical

Active, not recruiting

Brain EdemaPhase 1/Phase 2

Active, not recruiting

Intracerebral HemorrhagePreclinical

Active, not recruiting

Diabetes MellitusPhase 2

Active, not recruiting

HypoglycemiaPhase 2/Phase 3

Active, not recruiting

Multiple SclerosisPhase 1

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

glibenclamide

Novo Nordisk

Approved

6 2

Byetta

AstraZeneca

Preclinical

55 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 7

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 8

Forxiga

AstraZeneca

Preclinical

3 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

SGLT-2 Inhibitor

SSheffield Teaching Hospitals NHS Foundation Trust

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Hyperglycaemia

NCT05687500

Q3 2029

Phase 1Not yet recruiting

Multiple Sclerosis

NCT07221799

Clinical

Trials by Indication[1]

Type 2 Diabetes6 trials

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Completed·AAzienda Ospedaliero-Universitaria di Parma·Phase 3·NCT01822548·64 enrolled

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Completed·—·Phase 4·NCT02145611·50 enrolled

Risk of Hypoglycemia in Type 2 Diabetes

Completed·UUniversity of Giessen··NCT00734669·12 enrolled

Show 3 more trials

Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes

Terminated· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00267683·9 enrolled

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT00393718·400 enrolled

Evaluation of Cissus Verticillata L. Infusion in Controlling Type 2 Diabetes

Completed·FFederal University of Paraíba·Phase 1/2·NCT01145534·15 enrolled

Diabetes2 trials

Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT02375828·10 enrolled

Low dosE GlibENclamide in Diabetes Part A

Completed·UUniversity of Oxford·Phase 2·NCT02830048·16 enrolled

Hemodynamic2 trials

The Hemodynamic Effects of CGRP After Glibenclamide Administration in Healthy Volunteers

Completed·DDanish Headache Center·N/A·NCT04231617·20 enrolled

The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers

Completed·DDanish Headache Center·N/A·NCT04960657·22 enrolled

Brain Edema1 trial

To Evaluate the Effect of Glibenclamide in Reducing Brain Edema of TBI

Unknown status·—·Phase 1/2·NCT05148403·76 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT02318693·53 enrolled

18 more indications

LAM1 trial

GALLANT 4 Tesaglitazar vs. Glibenclamide

Terminated· AstraZeneca logo

AstraZeneca·Phase 3·NCT00255541·580 enrolled

Function1 trial

Do Sulphonylureas Preserve Cortical Function During Hypoglycaemia?

Unknown status·KKing's College Hospital NHS Trust·Phase 4·NCT00472875·10 enrolled

Subarachnoid Hemorrhage1 trial

Glibenclamide in Aneurysmatic Subarachnoid Hemorrhage

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT03569540·50 enrolled

GLP-11 trial

Cardioprotective Effects of GLP-1 and Their Mechanisms

Completed·PPapworth Hospital NHS Foundation Trust·Phase 1·NCT02128022·32 enrolled

ESS1 trial

Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study

Completed·KKhoo Teck Puat Hospital·Phase 4·NCT02201602·8 enrolled

Diabetes Mellitus1 trial

Efficacy and Safety Study of Sulfonylureas in Neonatal Diabetes Mellitus

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00610038·19 enrolled

Hypoglycemia1 trial

Sulfonylurea Effects on Glucagon Regulation During Hypoglycemia in Type 1 DM

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT00515801·18 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03284463·306 enrolled

Oxidative Stress1 trial

The Effect of Sitagliptin on Hypertension, Arterial Stiffness, Oxidative Stress and Inflammation

Unknown status·—·N/A·NCT00696982·60 enrolled

Acute1 trial

Evaluate the Use of Glibenclamide on Acute aSAH

Unknown status·—·Phase 4·NCT05137678·110 enrolled

Metformin1 trial

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Completed· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT04859452·56 enrolled

Hypertensive1 trial

Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT03089333·16 enrolled

Endothelial Dysfunction1 trial

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery

Completed·UUniversity of Campinas, Brazil·Phase 4·NCT02919345·98 enrolled

Intracerebral Hemorrhage1 trial

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage

Completed·XXijing Hospital·N/A·NCT03741530·220 enrolled

Hyperglycaemia1 trial

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05687500·35 enrolled

Multiple Sclerosis1 trial

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT07221799·10 enrolled

Gestational Diabetes1 trial

A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS

Completed·UUniversity of Edinburgh·Phase 3·NCT02080377·23 enrolled

Injury1 trial

Ischemic Injury and Ischemic Preconditioning in Diabetes

Completed·RRadboud University Medical Center··NCT00184821·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for glibenclamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — glibenclamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for glibenclamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novo Nordisk

glibenclamide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2029

Trials by Indication[1]

Type 2 Diabetes6 trials

Diabetes2 trials

Hemodynamic2 trials

Brain Edema1 trial

Type 2 Diabetes Mellitus1 trial

LAM1 trial

Function1 trial

Subarachnoid Hemorrhage1 trial

GLP-11 trial

ESS1 trial

Diabetes Mellitus1 trial

Hypoglycemia1 trial

Safety and Efficacy1 trial

Oxidative Stress1 trial

Acute1 trial

Metformin1 trial

Hypertensive1 trial

Endothelial Dysfunction1 trial

Intracerebral Hemorrhage1 trial

Hyperglycaemia1 trial

Multiple Sclerosis1 trial

Gestational Diabetes1 trial

Injury1 trial

References

Drug Info

Quick Facts

Related News